PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research

Abstract 3144: Targeting AR-SREBP crosstalk in prostate adenocarcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

SDSirisha DevarakondaPPPrashanth ParupathiEFEkniel Francois

Discussion

Loading...

Member takes

Overview

Evaluates fatostatin's anticancer effects in AR-positive prostate cancer, suggesting new therapeutic options.

Key Points

  • To investigate the potential of pharmacological inhibition of SREBPs as a therapeutic strategy in androgen receptor-positive prostate cancer.
  • Evaluated fatostatin in AR-positive (LNCaP and C4) and AR-negative (PC3 and Du145) prostate cancer cell lines.
  • Measured cell viability, proliferation, migration, and invasion post-treatment with fatostatin.
  • Assessed protein and mRNA expression levels of SREBPs and androgen receptor after treatment.
  • Conducted RNA-Seq to analyze molecular mechanisms involved.
  • Fatostatin inhibited viability, proliferation, migration, and invasion in all prostate cancer cell lines.
  • Significant reductions in the expression of SREBPs and androgen receptor in the fatostatin treatment group.
  • More substantial effects observed in AR-positive cell lines compared to AR-negative cell lines.
  • RNA-Seq indicated downregulation of genes linked to AR signaling and cholesterol homeostasis.

Cite This Study

Devarakonda et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd62a79560c99a0a35e9https://doi.org/10.1158/1538-7445.am2026-3144
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 3145: Pharmacologic inhibition of SREBP-driven lipogenesis suppresses metastatic progression in prostate cancer2026
  2. 2Abstract 2077: Exploring the multifaceted efficacy of de novo lipogenesis inhibitor in cancer therapy2024
  3. 3Abstract B060: Rewiring the serum response factor interactome to overcome treatment resistance in prostate cancer2026
  4. 4Abstract B010: Targeting SSTR1 to overcome resistance to androgen receptor signaling inhibition in prostate cancer2026
  5. 5Identification of druggable targets from the interactome of the Androgen Receptor and Serum Response Factor pathways in prostate cancer.2024 · 1 citations